1. Signaling Pathways
  2. Cytoskeleton
  3. Integrin

Integrin

Integrins, a family of heterodimeric adhesion receptors for diverse extracellular matrices, have consistently been implicated as crucial drivers of ovarian cancer development and progression. A number of the RGD-based members of the integrin family, including α5β1, and αvβ3 or αvβ5 integrins, are markedly elevated in aggressive ovarian tumors. These adhesion receptors appear to promote cell adhesion, survival, motility and invasion during ovarian tumor growth or metastatic progression. Importantly, the functions of these integrins are strongly dependent on the activation of focal adhesion kinase (FAK) and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways.

Integrins are transmembrane proteins and are major receptors for cell-extracellular matrix (ECM) and cell-cell adhesion. Modulation of these molecules, particularly αv integrin family, has exhibited profound effects on fibrosis in multiple organ and disease state. Based on the several studies, the integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been known to modulate the fibrotic process via activation of latent transforming growth factor (TGF)-β in pre-clinical models of fibrosis.

Each integrin is typically formed by the non-covalent pairing of one α subunit, of which, 18 types are known to exist, and one β subunit, of which 8 types are known to exist. Together, 24 distinct heterodimers have been identified to date. The αv subunit can form heterodimers with the β1, β3, β5, β6 or β8 subunits and β1 can associate with many different α subunits from α1 to α11, and αv, indicating that not all theoretically possible α and subunit pairs form. Interestingly, the activation of TGF-β appears to be a common function of multiple αv integrins.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10314A
    Lotrafiban hydrochloride
    Lotrafiban hydrochloride is an orally-active platelet GPIIb/IIIa blocker for research of coronary and cerebrovascular disease.
    Lotrafiban hydrochloride
  • HY-153481A
    ATL 1102 sodium
    Inhibitor
    ATL 1102 (Avicursen) sodium is a novel second-generation antisense oligonucleotide to CD49d mRNA
    ATL 1102 sodium
  • HY-172465
    DSPE-PEG5000-cRGD
    DSPE-PEG5000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG5000-cRGD can be used for drug delivery.
    DSPE-PEG5000-cRGD
  • HY-10307
    Roxifiban
    Inhibitor
    Roxifiban is a platelet glycoprotein (GP) IIb/IIIa receptor inhibitor that can be used in the study of angina.
    Roxifiban
  • HY-150124A
    K34c hydrochloride
    Antagonist
    K34c hydrochloride is a potent and selective α5β1 integrin antagonist. By inhibiting α5β1 integrin, K34c hydrochloride reduces chemotherapy-induced premature senescence and promotes apoptosis. K34c hydrochloride can be used in glioblastoma research.
    K34c hydrochloride
  • HY-N15519
    Crocatin B
    Inhibitor
    Crocatin B is found in P. crocatum Ruiz & Pav. Crocatin B exerts anti-inflammatory activity by inhibiting the expression of TNF-α and ICAM-1. Crocatin B has anti-tumor activity.
    Crocatin B
  • HY-118410
    L-738167
    L-738167 is an orally active fibrogen receptor antagonist that prevents the binding of fibrinogen to GP IIb/IIIa. L-738167 can be utilized in thrombus research.
    L-738167
  • HY-P0322A
    GRGDSPK TFA
    Inhibitor
    GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption.
    GRGDSPK TFA
  • HY-111348A
    Lamifiban TFA
    Antagonist
    Lamifiban TFA is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban TFA in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban TFA is promising for research of acute coronary syndromes.
    Lamifiban TFA
  • HY-136214
    R-BC154 acetate
    Antagonist
    R-BC154 acetate is a selective fluorescent α9β1 integrin antagonist. R-BC154 acetate acts as a useful high affinity, activation dependent integrin probe, which can be used to investigate α9β1 and α4β1 integrin binding activity.
    R-BC154 acetate
  • HY-P0295A
    Gly-Arg-Gly-Asp-Ser TFA
    Inhibitor
    Gly-Arg-Gly-Asp-Ser (TFA) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC50 of ∼5 and ∼6.5 μM.
    Gly-Arg-Gly-Asp-Ser TFA
  • HY-P1702
    GR83895
    Inhibitor
    GR83895 is a RGD based peptide, and inhibits ADP-induced platelet aggregation of human gel-filtered platelets (IC50= 0.9 μM).
    GR83895
  • HY-B0686A
    Eptifibatide monoacetate
    Inhibitor
    Eptifibatide monoacetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity.
    Eptifibatide monoacetate
  • HY-14189
    Valategrast hydrochloride
    Antagonist
    Valategrast hydrochloride (R-411) is a potent integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast hydrochloride has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment.
    Valategrast hydrochloride
  • HY-P10667
    Ac-MRGDH-NH2
    Ac-MRGDH-NH2 is a pentapeptide containing the RGD sequence. Ac-MRGDH-NH2 can be used to synthesize the diastereoisomeric prodrugs Λ- and Δ-[Ru(Ph2phen)2(κS,κN-(Ac-MRGDH-NH2))]Cl2. In these prodrugs, Ac-MRGDH-NH2 serves as a photolabile protecting group for the cytotoxic bis-aqua ruthenium warhead [Ru(Ph2phen)2(OH2)2]2+, and Ac-MRGDH-NH2 possesses integrin targeting ability and photosubstitution properties. Therefore, Ac-MRGDH-NH2 can be utilized in research on tumor-targeted photodynamic activation chemotherapy (PACT).
    Ac-MRGDH-NH2
  • HY-168087
    GSK3335103
    Inhibitor
    GSK3335103 is an orally active, non-peptide αvβ6 integrin inhibitor (pIC50=8). GSK3335103 can be used in the study of pulmonary fibrosis.
    GSK3335103
  • HY-P991652
    MINT1526A
    Inhibitor
    MINT1526A (RG-7594) is a humanized IgG1 monoclonal antibody inhibitor targeting α5β1 integrin. MINT1526A has significant anti-angiogenic activity. MINT1526A can be used for cancers research.
    MINT1526A
  • HY-P991604
    MLN2201
    Antagonist
    MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research.
    MLN2201
  • HY-111348
    Lamifiban
    Antagonist
    Lamifiban is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban is promising for research of acute coronary syndromes.
    Lamifiban
  • HY-P990857
    Anti-CD54/ICAM-1 Antibody (R6-5-D6)
    Inhibitor
    Anti-CD54/ICAM-1 Antibody (R6-5-D6) is a kind of mouse IgG2a chimeric antibody inhibitor, targeting to human CD54/ICAM-1. Anti-CD54/ICAM-1 Antibody (R6-5-D6) can block CD54 binding to its ligand Lymphocyte Function-Associated Antigen 1 (LFA-1). Anti-CD54/ICAM-1 Antibody (R6-5-D6) can be used for the researches of inflammation and immunology.
    Anti-CD54/ICAM-1 Antibody (R6-5-D6)
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.